南京农大绿盾植保大模型2.0上线,实现AI推理、引导问诊、病害图像识别等关键技术跃升
大农化网报道:近日,由南京农业大学研发的植保人工智能助手——绿盾植保完成2.0版本迭代升级并正式上线运行。新版本在完整继承既有农业知识技术底座的基础上,在AI自主推理、引导式智能问诊、田间病害图像识别、用户信息管理、多终端平台适配等方面实现…
叶菌唑原药登记证件已达13家,合成路线经多年优化改进趋于成熟
叶菌唑(metconazole)是日本吴羽化学工业株式会社1987年研发的三唑类杀菌剂、1992年在英国布赖顿植保会议上公开,后与壳牌公司(现巴斯夫)共同开发,迄今也已逾三十年。作为高内吸活性的三唑类杀菌剂,叶菌唑对小麦赤霉病表现出超高防效…
酒泉市农机购置与应用补贴政策实施风险防控培训班在玉门举办
为深入落实国家、省、市农机惠农补贴工作部署,进一步规范农机购置与应用补贴、农机报废更新补贴实施流程,压实监管责任,防范化解涉农资金风险,保障惠农补贴政策公平高效实施。9月22日–23日,酒泉市农机购置与应用补贴政策实施风险防…
酒泉市及肃州区农机中心开展制种玉米收获机现场演示暨农机安全生产培训活动
九月的肃州,金风送爽,气候宜人。为充分展现农机科技赋能农业丰收的强劲力量,加速破解制种玉米机械化收获瓶颈,抓实农机节粮减损,筑牢“三秋”农机安全防线,近日,酒泉市及肃州区农机中心在上坝镇旧墩村千亩制种玉米种植基地…
补齐短板:两年机具迭代推广 赋能平潭甘薯产业全程机械化
为持续推进农业“五新”推广,补齐甘薯机械化生产短板,福建省平潭综合实验区连续两年开展甘薯专用农机试验示范与现场观摩活动,通过机具迭代适配、分类推广应用,健全完善本地甘薯机械化作业体系。2026年平潭综合实验区农业…
🎥 Resurrect Bio reawakens plants’ natural defenses: ‘It’s very targeted, almost like personalized medicine’
[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Resurrect Bio] In the evolutionary arms race betwee…
Farmhub Agro Services Returns as Agro-Economy Partner for Africa Blockchain Festival 2026
36 Nigerian agritech firm Farmhub Agro Services has been confirmed as the Agro-Economy Partner for the Africa Blockchain…
Tresalis acquires well-being fragrance brand Vyrao in debut beauty acquisition
Tresalis has acquired well-being fragrance house Vyrao. The new owner-operator platform focuses on acquiring and growing science- and efficacy-led consumer health, beauty, and wellness brands.
UCD and Teagasc Launch Third FAST-IP Programme to Develop Next Generation of Agritech Start-ups
39 University College Dublin and Teagasc have launched the third edition of their Food and Agriculture Sustainable Techn…
CSL backs Swiss Alentis’ claudin-1 bet with up to $1.6bn deal
An exclusive global partnership of Basel-based Alentis Therapeutics with Australian CSL aims at co-developing and co-commercializing lixudebart, an investigational antibody targeting claudin-1. The agreement gives CSL a leading role in a clinical program that Alentis has built around its proprietary claudin-1 platform. CSL will also take on the financial burden of development, including the ongoing Phase II RENAL trial, a planned Phase III study in AAV-RPGN and additional Phase II trials in focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis (PSC).
